We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Chimeric form of tumor necrosis factor-α has enhanced surface expression and antitumor activity.
- Authors
Rieger, R.; Whitacre, D.; Cantwell, M. J.; Prussak, C.; Kipps, T. J.
- Abstract
Tumor necrosis factor (TNF)-α is a type-II transmembrane protein that is cleaved by TNF-α-converting enzyme (TACE/ADAM-17) to release soluble TNF, a cytokine with potent antitumor properties whose use in clinical applications is limited by its severe systemic toxicity. We found that human cells transfected with vectors encoding TNF without the TACE cleavage site (ΔTACE-TNF) still released functional cytokine at substantial levels that varied between transfected cell lines of different tissue types. Vectors encoding membrane-associated domains of CD154, another TNF-family protein, conjoined with the carboxyl-terminal domain of TNF, directed higher-level surface expression of a functional TNF that, in contrast to ΔTACE-TNF, was resistant to cleavage in all cell types. Furthermore, adenovirus vectors encoding CD154-TNF had significantly greater in vivo biological activity in inducing regression of established, syngeneic tumors in mice than adenovirus vectors encoding TNF, and lacked toxicity associated with soluble TNF. As such, CD154-TNF is a novel TNF that appears superior for treatment of tumors in which high-level local expression of TNF is desired.Cancer Gene Therapy (2009) 16, 53–64; doi:10.1038/cgt.2008.57; published online 25 July 2008
- Subjects
TUMOR necrosis factors; CYTOKINES; CELL lines; GLYCOPROTEINS; TUMORS
- Publication
Cancer Gene Therapy, 2009, Vol 16, Issue 1, p53
- ISSN
0929-1903
- Publication type
Article
- DOI
10.1038/cgt.2008.57